Cargando…

Abacavir Use and Risk for Myocardial Infarction and Coronary Artery Disease: Updated Meta-analysis of Data from Clinical Trials

BACKGROUND: Several observational studies and randomized controlled trials (RCTs) have suggested an association between abacavir (ABC) use and myocardial infarction (MI) but others, including meta-analyses of clinical trial data, have not. METHODS: This updated meta-analysis estimates exposure-adjus...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nan, Cassandra, Shaefer, Mark S, Urbaityte, Rimgaile, Oyee, James, Hopking, Judy, Ragone, Leigh, McCoig, Cynthia, Vannappagari, Vani
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2017
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5632185/ http://dx.doi.org/10.1093/ofid/ofx163.431

Ejemplares similares

Abacavir Use and Risk for Myocardial Infarction and Cardiovascular Events: Pooled Analysis of Data From Clinical Trials
por: Nan, Cassandra, et al.
Publicado: (2018)

Abacavir Hypersensitivity Reaction Reporting Rates During a Decade of HLA‐B*5701 Screening as a Risk‐Mitigation Measure
por: Stainsby, Chris M., et al.
Publicado: (2018)

HLA-B*57:01 screening and hypersensitivity reaction to abacavir between 1999 and 2016 in the OPERA(®) observational database: a cohort study
por: Mounzer, Karam, et al.
Publicado: (2019)

A retrospective clinical audit of general practices in Australia to determine the motivation for switch to dolutegravir/abacavir/lamivudine and clinical outcomes
por: Ferrer, Pedro E, et al.
Publicado: (2017)

Pharmacokinetics, Safety, and Tolerability of a Single Oral Dose of Abacavir/Dolutegravir/Lamivudine Combination Tablets in Healthy Japanese Study Participants
por: Singh, Rajendra P., et al.
Publicado: (2021)

Effect of Sorbitol on the Pharmacokinetic Profile of Lamivudine Oral Solution in Adults: An Open‐Label, Randomized Study
por: Adkison, Kimberly, et al.
Publicado: (2017)

936. Body Fat Redistribution/Accumulation, Pancreatic Disorders, Musculoskeletal Disorders, IRIS, Severe Systemic Rash and Hypersensitivity Reactions Following Initiation of Commonly Prescribed Antiretrovirals
por: Lackey, Philip, et al.
Publicado: (2018)

Two‐drug antiretroviral regimens: an assessment of virologic response and durability among treatment‐experienced persons living with HIV in the OPERA(®) Observational Database
por: Pierone, Gerald, et al.
Publicado: (2019)

2483. Characteristics and Outcomes Over First 12 Months of a Two-Drug Regimen (Dolutegravir/Rilpivirine) for Treatment of HIV-1 in the United States
por: Pierone, Gerald, et al.
Publicado: (2019)

Acute myocardial infarction associated with abacavir and tenofovir based antiretroviral drug combinations in the United States
por: Dorjee, Kunchok, et al.
Publicado: (2021)

Is there continued evidence for an association between abacavir usage and myocardial infarction risk in individuals with HIV? A cohort collaboration
por: Sabin, Caroline A., et al.
Publicado: (2016)

2085. PrEP Interest and Preferences Among US Black and Hispanic Men – A National Survey
por: Poteat, Tonia, et al.
Publicado: (2022)

Abacavir forms novel cross-linking abacavir protein adducts in patients
por: Meng, Xiaoli, et al.
Publicado: (2014)

1549. Risk Factors, Risk Perception, and Long-acting PrEP Awareness and Interest among US Women: A National Survey
por: Poteat, Tonia, et al.
Publicado: (2023)

74. Maternal Dolutegravir (DTG) Use During Pregnancy and Birth Outcomes: The Antiretroviral Pregnancy Registry (APR)
por: Vannappagari, Vani, et al.
Publicado: (2021)

Twenty-Five Years of Lamivudine: Current and Future Use for the Treatment of HIV-1 Infection
por: Quercia, Romina, et al.
Publicado: (2018)

LB-8. Summary of COVID-Related Impact on Cabotegravir and Rilpivirine Long-Acting (CAB+RPV LA) Dosing Across the Six Ongoing Global Phase IIb and IIIb Clinical Trials
por: D'Amico, Ronald, et al.
Publicado: (2020)

Abacavir-induced liver toxicity
por: Pezzani, Maria Diletta, et al.
Publicado: (2016)

Response by gender of HIV-1-infected subjects treated with abacavir/lamivudine plus atazanavir, with or without ritonavir, for 144 weeks
por: Squires, Kathleen E, et al.
Publicado: (2017)

Similar neurocognitive outcomes after 48 weeks in HIV-1-infected participants randomized to continue tenofovir/emtricitabine + atazanavir/ritonavir or simplify to abacavir/lamivudine + atazanavir
por: Robertson, Kevin, et al.
Publicado: (2018)

HLA-B*57:01 allele prevalence in HIV-infected North American subjects and the impact of allele testing on the incidence of abacavir-associated hypersensitivity reaction in HLA-B*57:01-negative subjects
por: Small, Catherine Butkus, et al.
Publicado: (2017)

Pregnancy and Neonatal Outcomes Following Prenatal Exposure to Dolutegravir
por: Vannappagari, Vani, et al.
Publicado: (2019)

Abacavir methanol 2.5-solvate
por: Pham, Phuong-Truc T.
Publicado: (2009)

Alopecia Areata Associated with Abacavir Therapy
por: Kim, Hee-Sung, et al.
Publicado: (2014)

Myocardial Infarction With Non-obstructive Coronary Arteries: An Updated Overview of Pathophysiology, Diagnosis, and Management
por: Khan, Arshan, et al.
Publicado: (2022)

Quaking Regulates Hnrnpa1 Expression through Its 3′ UTR in Oligodendrocyte Precursor Cells
por: Zearfoss, N. Ruth, et al.
Publicado: (2011)

The ASSURE study: HIV‐1 suppression is maintained with bone and renal biomarker improvement 48 weeks after ritonavir discontinuation and randomized switch to abacavir/lamivudine + atazanavir
por: Wohl, DA, et al.
Publicado: (2015)

Relaxation Effect of Abacavir on Rat Basilar Arteries
por: Li, Rachel Wai Sum, et al.
Publicado: (2015)

Structural Elements Recognized by Abacavir-Induced T Cells
por: Yerly, Daniel, et al.
Publicado: (2017)

Abacavir use is associated with increased prothrombin conversion
por: Yan, Qiuting, et al.
Publicado: (2023)

Changes over time in creatinine clearance and comparison of emergent adverse events for HIV-positive adults receiving standard doses (300 mg/day) of lamivudine-containing antiretroviral therapy with baseline creatinine clearance of 30–49 vs ≥50 mL/min
por: Ross, Lisa L., et al.
Publicado: (2019)

AOP-Based Transformation of Abacavir in Different Environments: Evolution Profile of Descyclopropyl-Abacavir and In Silico Toxicity Assessment of the Main Transformation Products
por: Evgenidou, Eleni, et al.
Publicado: (2023)

Estudio prospectivo para estimar la carga de hospitalización y visitas a urgencias de la gripe en población pediátrica en Bilbao (2010-2011)()
por: Ortiz-Lana, Naiara, et al.
Publicado: (2017)

A prospective study to assess the burden of influenza-related hospitalizations and emergency department visits among children in Bilbao, Spain (2010–2011)()()
por: Ortiz-Lana, Naiara, et al.
Publicado: (2017)

Simplification to Abacavir/Lamivudine + Atazanavir Maintains Viral Suppression and Improves Bone and Renal Biomarkers in ASSURE, a Randomized, Open Label, Non-Inferiority Trial
por: Wohl, David A., et al.
Publicado: (2014)

Abacavir/lamivudine combination in the treatment of HIV: a review
por: Sivasubramanian, Geetha, et al.
Publicado: (2010)

HLA-B*5701 testing to predict abacavir hypersensitivity
por: Ma, Joseph D., et al.
Publicado: (2010)

ProTide generated long-acting abacavir nanoformulations
por: Lin, Zhiyi, et al.
Publicado: (2018)

The Role of Conformational Dynamics in Abacavir-Induced Hypersensitivity Syndrome
por: Fodor, James, et al.
Publicado: (2019)

Prevalence of and risk for gastrointestinal bleeding and peptic ulcerative disorders in a cohort of HIV patients from a U.S. healthcare claims database
por: Bratton, Emily, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_3ji4i5pu382mp05ngpt9o2e8n5